JNJ

237.25

+0.8%↑

UNH

268

-3.16%↓

TMO

549.47

-3.13%↓

ABT

108.73

-0.65%↓

ISRG

478.55

-0.02%↓

JNJ

237.25

+0.8%↑

UNH

268

-3.16%↓

TMO

549.47

-3.13%↓

ABT

108.73

-0.65%↓

ISRG

478.55

-0.02%↓

JNJ

237.25

+0.8%↑

UNH

268

-3.16%↓

TMO

549.47

-3.13%↓

ABT

108.73

-0.65%↓

ISRG

478.55

-0.02%↓

JNJ

237.25

+0.8%↑

UNH

268

-3.16%↓

TMO

549.47

-3.13%↓

ABT

108.73

-0.65%↓

ISRG

478.55

-0.02%↓

JNJ

237.25

+0.8%↑

UNH

268

-3.16%↓

TMO

549.47

-3.13%↓

ABT

108.73

-0.65%↓

ISRG

478.55

-0.02%↓

Home・Aandelen Lijst・Celldex Therapeutics Inc

Celldex Therapeutics Inc

Open

SectorGezondheidszorg

23.38 -2.87

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

23.4

Max

24.5

Belangrijke statistieken
By Trading Economics
Inkomsten	-10M -67M
Winstmarge	-7,753.425
Werknemers	186
EBITDA	-9.8M -73M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+112.55% upside

Dividenden
By Dow Jones
Volgende Winsten	25 feb 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	133M 1.6B
Vorige openingsprijs	26.25
Vorige sluitingsprijs	23.38

Nieuwssentiment

By Acuity

50%

151 / 352 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Weak Bullish Evidence

18.91 / 20.63 Steun & Weerstand

Celldex Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

5 feb 2026, 00:00 UTC

Populaire aandelen

Stocks to Watch: Crown Castle, Qualcomm, Arm, U-Haul

4 feb 2026, 22:55 UTC

Winsten

Qualcomm 1Q Sales Rise, But Memory Shortage Dents Outlook -- Update

4 feb 2026, 21:44 UTC

Winsten

Arm Holdings 3Q Profit Falls Despite Revenue Growth

4 feb 2026, 21:39 UTC

Winsten

Qualcomm 1Q Sales Rise, But Memory Shortage Dents Outlook

5 feb 2026, 00:00 UTC

Winsten

Renesas Electronics FY Loss Y51.76B Vs Net Y219.08B

5 feb 2026, 00:00 UTC

Winsten

Renesas Electronics FY Loss Y51.76B Vs Net Y219.08B

4 feb 2026, 23:46 UTC

Marktinformatie

Nikkei May Rise as Weaker Yen Supports Earnings Hopes -- Market Talk

4 feb 2026, 23:45 UTC

Winsten

Google to Double Spending as Earnings Beat Wall Street Expectations -- 4th Update

4 feb 2026, 23:32 UTC

Marktinformatie

Gold Rises on Possible Dip-Buying Amid Lingering U.S.-Iran Tensions -- Market Talk

4 feb 2026, 22:59 UTC

Acquisities, Fusies, Overnames

SiTime to Buy Timing Business From Renesas Electronics For $1.5B

4 feb 2026, 22:30 UTC

Winsten

Salesforce Stock Is Battered, and Super Cheap. Hang Tight. -- Barrons.com

4 feb 2026, 22:30 UTC

Winsten

Alphabet's Cloud Is Shining as CapEx Heads Even Higher -- Barrons.com

4 feb 2026, 22:21 UTC

Winsten

Snap Stock Pops After Surprise Earnings Beat -- Barrons.com

4 feb 2026, 22:17 UTC

Marktinformatie

WiseTech Faces Risks in Both Directions From DSV's Progress -- Market Talk

4 feb 2026, 22:15 UTC

Marktinformatie

Santos Should Lay Out Strategic Plans at Annual Result -- Market Talk

4 feb 2026, 22:00 UTC

Marktinformatie

ESG Roundup: Market Talk

4 feb 2026, 21:53 UTC

Winsten

Google to Double Spending as Earnings Beat Wall Street Expectations -- 3rd Update

4 feb 2026, 21:51 UTC

Winsten

Snap Stock Pops After Surprise Earnings Beat -- Barrons.com

4 feb 2026, 21:50 UTC

Marktinformatie

Tech, Media & Telecom Roundup: Market Talk

4 feb 2026, 21:50 UTC

Marktinformatie

Acquisities, Fusies, Overnames

Financial Services Roundup: Market Talk

4 feb 2026, 21:50 UTC

Marktinformatie

Winsten

Auto & Transport Roundup: Market Talk

4 feb 2026, 21:50 UTC

Marktinformatie

Health Care Roundup: Market Talk

4 feb 2026, 21:45 UTC

Winsten

Arm Holdings Reported Record Revenue. The Stock is Falling. -- Barrons.com

4 feb 2026, 21:44 UTC

Winsten

Qualcomm Gives Weak Guidance. The CEO Blames Memory Crunch. -- Barrons.com

4 feb 2026, 21:43 UTC

Winsten

Google to Double Spending as Earnings Beat Wall Street Expectations -- 2nd Update

4 feb 2026, 21:41 UTC

Winsten

These Stocks Are Today's Movers: AMD, AbbVie, Boston Scientific, Eli Lilly, MP Materials, Super Micro, Palantir, and More -- Barrons.com

4 feb 2026, 21:36 UTC

Marktinformatie

Latest Canada Green Bond Raises C$2 Billion -- Market Talk

4 feb 2026, 21:30 UTC

Winsten

Alphabet Reports Solid Earnings. CapEx Heads Even Higher. -- Barrons.com

4 feb 2026, 21:30 UTC

Winsten

Alphabet Reports Solid Earnings. CapEx Heads Even Higher. -- Barrons.com

4 feb 2026, 21:30 UTC

Winsten

Beach Energy Interim Dividend 1 Australian Cent/Sjare

Peer Vergelijking

Prijswijziging

Celldex Therapeutics Inc Prognose

Koersdoel

By TipRanks

112.55% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 53.5 USD 112.55%

Hoogste 90 USD

Laagste 24 USD

Gebaseerd op 9 Wall Street-analisten die 12-maands prijsdoelen bieden voor Celldex Therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

9 ratings

Buy

Hold

Sell

Gebaseerd op 9 analisten die aandelenratings hebben gegeven aan Celldex Therapeutics Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

18.91 / 20.63Steun & Weerstand

Recent bullish events outweigh bearish events.

All events are bearish.

Sentiment

By Acuity

151 / 352 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Celldex Therapeutics Inc

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.